Midazolam Limited Sampling Strategy With a Population Pharmacokinetic Approach to Simultaneously Estimate Cytochrome P450 (CYP) 3A Constitutive, Inhibition, and Induction/Activation Conditions in Healthy Adults

2019 ◽  
Vol 59 (11) ◽  
pp. 1495-1504
Author(s):  
Jincheng Yang ◽  
Mina Nikanjam ◽  
Edmund V. Capparelli ◽  
Shirley M. Tsunoda ◽  
Howard E. Greenberg ◽  
...  
Keyword(s):  
Cytochrome P450 ◽  
Sampling Strategy ◽  
Healthy Adults ◽  
Limited Sampling Strategy ◽  
Population Pharmacokinetic ◽  
Limited Sampling ◽  
Activation Conditions ◽  
Cyp 3A ◽  
Pharmacokinetic Approach

Midazolam Single Time Point Concentrations to Estimate Exposure and Cytochrome P450 (CYP) 3A Constitutive Activity Utilizing Limited Sampling Strategy With a Population Pharmacokinetic Approach

2018 ◽  
Vol 58 (9) ◽  
pp. 1205-1213 ◽  
Author(s):  
Jincheng Yang ◽  
Maulik Patel ◽  
Mina Nikanjam ◽  
Edmund V. Capparelli ◽  
Shirley M. Tsunoda ◽  
...  
Keyword(s):  
Cytochrome P450 ◽  
Sampling Strategy ◽  
Population Pharmacokinetic ◽  
Constitutive Activity ◽  
Single Time ◽  
Limited Sampling ◽  
Cyp 3A ◽  
Pharmacokinetic Approach ◽  
Single Time Point ◽  
Time Point

scholarly journals Pharmacokinetic Modeling and Limited Sampling Strategies Based on Healthy Volunteers for Monitoring of Ertapenem in Patients with Multidrug-Resistant Tuberculosis

2017 ◽  
Vol 61 (4) ◽  
Author(s):  
S. P. van Rijn ◽  
M. A. Zuur ◽  
R. van Altena ◽  
O. W. Akkerman ◽  
J. H. Proost ◽  
...  
Keyword(s):  
Healthy Volunteers ◽  
Population Pharmacokinetic Model ◽  
Pharmacokinetic Model ◽  
Sampling Strategy ◽  
Free Fraction ◽  
Limited Sampling Strategy ◽  
Population Pharmacokinetic ◽  
Time Curve ◽  
Limited Sampling ◽  
Mdr Tb

ABSTRACT Ertapenem is a broad-spectrum carbapenem antibiotic whose activity against Mycobacterium tuberculosis is being explored. Carbapenems have antibacterial activity when the plasma concentration exceeds the MIC at least 40% of the time (40% T MIC). To assess the 40% T MIC in multidrug-resistant tuberculosis (MDR-TB) patients, a limited sampling strategy was developed using a population pharmacokinetic model based on data for healthy volunteers. A two-compartment population pharmacokinetic model was developed with data for 42 healthy volunteers using an iterative two-stage Bayesian method. External validation was performed by Bayesian fitting of the model developed with data for volunteers to the data for individual MDR-TB patients (in which the fitted values of the area under the concentration-time curve from 0 to 24 h [AUC0–24, fit values] were used) using the population model developed for volunteers as a prior. A Monte Carlo simulation (n = 1,000) was used to evaluate limited sampling strategies. Additionally, the 40% T MIC with the free fraction (f 40% T MIC) of ertapenem in MDR-TB patients was estimated with the population pharmacokinetic model. The population pharmacokinetic model that was developed was shown to overestimate the area under the concentration-time curve from 0 to 24 h (AUC0–24) in MDR-TB patients by 6.8% (range, −17.2 to 30.7%). The best-performing limited sampling strategy, which had a time restriction of 0 to 6 h, was found to be sampling at 1 and 5 h (r 2 = 0.78, mean prediction error = −0.33%, root mean square error = 5.5%). Drug exposure was overestimated by a mean percentage of 4.2% (range, −15.2 to 23.6%). When a free fraction of 5% was considered and the MIC was set at 0.5 mg/liter, the minimum f 40% T MIC would have been exceeded in 9 out of 12 patients. A population pharmacokinetic model and limited sampling strategy, developed using data from healthy volunteers, were shown to be adequate to predict ertapenem exposure in MDR-TB patients.

scholarly journals Limited Sampling Strategy of Partial Area Under the Concentration–Time Curves to Estimate Midazolam Systemic Clearance for Cytochrome P450 3A Phenotyping

2015 ◽  
Vol 37 (1) ◽  
pp. 84-89 ◽  
Author(s):  
Joanna C. Masters ◽  
Denise M. Harano ◽  
Howard E. Greenberg ◽  
Shirley M. Tsunoda ◽  
In-Jin Jang ◽  
...  
Keyword(s):  
Cytochrome P450 ◽  
Sampling Strategy ◽  
Limited Sampling Strategy ◽  
Systemic Clearance ◽  
Cytochrome P450 3A ◽  
Limited Sampling ◽  
Concentration Time ◽  
Partial Area

P.143 Population pharmacokinetic model and limited sampling strategy for clozapine using plasma and dried blood spot samples

2020 ◽  
Vol 40 ◽  
pp. S88
Author(s):  
L.M. Geers ◽  
D. Cohen ◽  
L.M. Wehkamp ◽  
K. Van Hateren ◽  
H.J. Van Wattum ◽  
...  
Keyword(s):  
Population Pharmacokinetic Model ◽  
Pharmacokinetic Model ◽  
Sampling Strategy ◽  
Dried Blood Spot ◽  
Limited Sampling Strategy ◽  
Population Pharmacokinetic ◽  
Limited Sampling ◽  
Blood Spot

scholarly journals Limited Sampling Strategy for Determination of Ibrutinib Plasma Exposure: Joint Analyses with Metabolite Data

2021 ◽  
Vol 14 (2) ◽  
pp. 162
Author(s):  
Félicien Le Louedec ◽  
Fanny Gallais ◽  
Fabienne Thomas ◽  
Mélanie White-Koning ◽  
Ben Allal ◽  
...  
Keyword(s):  
Area Under The Curve ◽  
Sampling Strategy ◽  
Predictive Performance ◽  
Pharmacokinetic Profile ◽  
Limited Sampling Strategy ◽  
Joint Analysis ◽  
Therapeutic Drug ◽  
Post Dose ◽  
Limited Sampling ◽  
Three Samples

Therapeutic drug monitoring of ibrutinib is based on the area under the curve of concentration vs. time (AUCIBRU) instead of trough concentration (Cmin,ss) because of a limited accumulation in plasma. Our objective was to identify a limited sampling strategy (LSS) to estimate AUCIBRU associated with Bayesian estimation. The actual AUCIBRU of 85 patients was determined by the Bayesian analysis of the full pharmacokinetic profile of ibrutinib concentrations (pre-dose T0 and 0.5, 1, 2, 4 and 6 h post-dose) and experimental AUCIBRU were derived considering combinations of one to four sampling times. The T0–1–2–4 design was the most accurate LSS (root-mean-square error RMSE = 11.0%), and three-point strategies removing the 1 h or 2 h points (RMSE = 22.7% and 14.5%, respectively) also showed good accuracy. The correlation between the actual AUCIBRU and Cmin,ss was poor (r2 = 0.25). The joint analysis of dihydrodiol-ibrutinib metabolite concentrations did not improve the predictive performance of AUCIBRU. These results were confirmed in a prospective validation cohort (n = 27 patients). At least three samples, within the pre-dose and 4 h post-dose period, are necessary to estimate ibrutinib exposure accurately.

scholarly journals A limited sampling strategy to estimate individual pharmacokinetic parameters of methotrexate in children with acute lymphoblastic leukemia

2007 ◽  
Vol 60 (4) ◽  
pp. 621-621 ◽  
Author(s):  
Christine Plard ◽  
Françoise Bressolle ◽  
May Fakhoury ◽  
Daolun Zhang ◽  
Karina Yacouben ◽  
...  
Keyword(s):  
Acute Lymphoblastic Leukemia ◽  
Lymphoblastic Leukemia ◽  
Sampling Strategy ◽  
Limited Sampling Strategy ◽  
Pharmacokinetic Parameters ◽  
Limited Sampling

Determination of mycophenolate area under the curve by limited sampling strategy

2001 ◽  
Vol 33 (1-2) ◽  
pp. 1052-1053 ◽  
Author(s):  
S Yeung ◽  
K.L Tong ◽  
W.K Tsang ◽  
H.L Tang ◽  
K.S Fung ◽  
...  
Keyword(s):  
Area Under The Curve ◽  
Sampling Strategy ◽  
Limited Sampling Strategy ◽  
Limited Sampling
Sign in / Sign up

Export Citation Format

Share Document